{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:36:04Z","timestamp":1789058164464,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","award":["N\u00b0 BD-8831"],"award-info":[{"award-number":["N\u00b0 BD-8831"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007526","name":"Universit\u00e9 Fran\u00e7ois-Rabelais","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007526","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.micpath.2021.105312","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T20:35:19Z","timestamp":1637699719000},"page":"105312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Co-delivery of PLGA nanoparticles loaded with rSAG1 antigen and TLR ligands: An efficient vaccine against chronic toxoplasmosis"],"prefix":"10.1016","volume":"162","author":[{"given":"Mojgan","family":"Allahyari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Golkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pezhman","family":"Fard-Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Dimier-Poisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6784-8549","authenticated-orcid":false,"given":"Marie-No\u00eblle","family":"M\u00e9v\u00e9lec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.micpath.2021.105312_bib1","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0020-7519(00)00124-7","article-title":"Toxoplasma gondii: from animals to humans","volume":"30","author":"Tenter","year":"2000","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.micpath.2021.105312_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.fawpar.2019.e00053","article-title":"A one health approach to vaccines against Toxoplasma gondii","volume":"15","author":"Innes","year":"2019","journal-title":"Food Waterborne Parasitol."},{"key":"10.1016\/j.micpath.2021.105312_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00057-17","article-title":"Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice","volume":"31","author":"Dunay","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.micpath.2021.105312_bib4","doi-asserted-by":"crossref","first-page":"607198","DOI":"10.3389\/fcimb.2020.607198","article-title":"Key limitations and new insights into the Toxoplasma gondii parasite stage switching for future vaccine development in human, livestock, and cats","volume":"10","author":"M\u00e9v\u00e9lec","year":"2020","journal-title":"Front. Cell Infect Microbiol."},{"key":"10.1016\/j.micpath.2021.105312_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0353-9","article-title":"Innate, adaptive, and cell-autonomous immunity againstToxoplasma gondii infection","volume":"51","author":"Sasai","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.micpath.2021.105312_bib6","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.4049\/jimmunol.164.5.2629","article-title":"Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase","volume":"164","author":"Kang","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.micpath.2021.105312_bib7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1756-3305-7-180","article-title":"Research progress on surface antigen 1 (SAG1) of Toxoplasma gondii","volume":"7","author":"Wang","year":"2014","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.micpath.2021.105312_bib8","doi-asserted-by":"crossref","first-page":"101414","DOI":"10.1016\/j.cimid.2020.101414","article-title":"Toxoplasma gondii surface antigen 1 (SAG1) as a potential candidate to develop vaccine against toxoplasmosis: a systematic review","volume":"69","author":"Pagheh","year":"2020","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"10.1016\/j.micpath.2021.105312_bib9","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1080\/21645515.2015.1102804","article-title":"Peptide\/protein vaccine delivery system based on PLGA particles","volume":"12","author":"Allahyari","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.micpath.2021.105312_bib10","doi-asserted-by":"crossref","first-page":"101327","DOI":"10.1016\/j.jddst.2019.101327","article-title":"In-vitroandin-vivocomparison of rSAG1-loaded PLGA prepared byencapsulation and adsorption methods as an efficient vaccine against","volume":"55","author":"Allahyari","year":"2020","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.micpath.2021.105312_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1756-3305-6-34","article-title":"Induction of long-lasting protective immunity against Toxoplasma gondii in BALB\/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles","volume":"6","author":"Chuang","year":"2013","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.micpath.2021.105312_bib12","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1016\/j.vaccine.2018.08.068","article-title":"Characterization of a multi-epitope peptide with selective MHC-binding capabilities encapsulated in PLGA nanoparticles as a novel vaccine candidate against Toxoplasma gondii infection","volume":"36","author":"Roozbehani","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2021.105312_bib13","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.exppara.2013.04.002","article-title":"Encapsulation of chimeric protein rSAG1\/2 into poly(lactide-co-glycolide) microparticles induces long-term protective immunity against Toxoplasma gondii in mice","volume":"134","author":"Chuang","year":"2013","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.micpath.2021.105312_bib14","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1038\/cti.2016.22","article-title":"Toll-like receptors: the swiss army knife of immunity and vaccine development","volume":"5","author":"Dowling","year":"2016","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.micpath.2021.105312_bib15","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1016\/j.vaccine.2007.02.057","article-title":"Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice","volume":"25","author":"Golkar","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2021.105312_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12879-016-2147-1","article-title":"Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii","volume":"17","author":"Song","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.micpath.2021.105312_bib17","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.1365-2230.2002.01151.x","article-title":"Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential","volume":"27","author":"Stanley","year":"2002","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.micpath.2021.105312_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3389\/fcimb.2020.00387","article-title":"Effect of imiquimod on tachyzoites of Toxoplasma gondii and infected macrophages in vitro and in BALB\/c mice","volume":"10","author":"Zaki","year":"2020","journal-title":"Front. Cell Infect Microbiol."},{"key":"10.1016\/j.micpath.2021.105312_bib19","doi-asserted-by":"crossref","first-page":"629917","DOI":"10.3389\/fimmu.2021.629917","article-title":"Imiquimod targets toxoplasmosis through modulating host toll-like receptor-MyD88 signaling","volume":"12","author":"Hamie","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2021.105312_bib20","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/jbm.a.31019","article-title":"Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly (D,L-lactic-co-glycolic acid) nanoparticles","volume":"81","author":"Hamdy","year":"2007","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.micpath.2021.105312_bib21","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.vaccine.2014.02.027","article-title":"Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release","volume":"32","author":"Ilyinskii","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2021.105312_bib22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1124\/jpet.118.254953","article-title":"Poly (d,l-lactide-co-glycolide) nanoparticles as delivery platforms for TLR7\/8 agonist-based cancer vaccine","volume":"370","author":"Kim","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.micpath.2021.105312_bib23","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1023\/A:1026498209874","article-title":"Protein instability in poly (lactic-co-glycolic acid) microparticles","volume":"17","author":"van de Weert","year":"2000","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.micpath.2021.105312_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jim.2014.11.012","article-title":"Production of in-vitro refolded and highly antigenic SAG1 for development of a sensitive and specific Toxoplasma IgG ELISA","volume":"416","author":"Allahyari","year":"2015","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.micpath.2021.105312_bib25","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.exppara.2016.09.008","article-title":"Synergistic effect of rSAG1 and rGRA2 antigens formulated in PLGA microspheres in eliciting immune protection against Toxoplasama gondii","volume":"170","author":"Allahyari","year":"2016","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.micpath.2021.105312_bib26","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jconrel.2005.10.010","article-title":"Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency","volume":"110","author":"Kazzaz","year":"2006","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.micpath.2021.105312_bib27","doi-asserted-by":"crossref","first-page":"6222","DOI":"10.1128\/IAI.71.11.6222-6228.2003","article-title":"The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis","volume":"71","author":"Ismael","year":"2003","journal-title":"Infect. Immun."},{"issue":"Pt 1","key":"10.1016\/j.micpath.2021.105312_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0031182000066695","article-title":"Surface antigens of Toxoplasma gondii","volume":"97","author":"Couvreur","year":"1988","journal-title":"Parasitology"},{"key":"10.1016\/j.micpath.2021.105312_bib29","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/21691401.2018.1478421","article-title":"Induction of Th1 type-oriented humoral response through intranasal immunization of mice with SAG1-Toxoplasma gondii polymeric nanospheres","volume":"46","author":"Naeem","year":"2018","journal-title":"Artif. Cells Nanomed Biotechnol."},{"key":"10.1016\/j.micpath.2021.105312_bib30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.micpath.2021.105312_bib31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.micpath.2021.105312_bib32","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s11095-011-0459-9","article-title":"Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles","volume":"28","author":"Hamdy","year":"2011","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.micpath.2021.105312_bib33","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0161-5890(97)00133-8","article-title":"Differences in immunological response to a T. gondii protein (SAG1) derived peptide between two strains of mice: effect on protection in T. gondii infection","volume":"34","author":"Velge-Roussel","year":"1997","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.micpath.2021.105312_bib34","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1128\/IAI.67.12.6358-6363.1999","article-title":"Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene","volume":"67","author":"Nielsen","year":"1999","journal-title":"Infect. Immun."},{"key":"10.1016\/j.micpath.2021.105312_bib35","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.4049\/jimmunol.150.9.3951","article-title":"Antibodies to Toxoplasma gondii major surface protein (SAG-1, P30) inhibit infection of host cells and are produced in murine intestine after peroral infection","volume":"150","author":"Mineo","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.micpath.2021.105312_bib36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1017\/S0031182001008460","article-title":"Anti-SAG1 peptide antibodies inhibit the penetration of Toxoplasma gondii tachyzoites into enterocyte cell lines","volume":"123","author":"Velge-Roussel","year":"2001","journal-title":"Parasitology"},{"key":"10.1016\/j.micpath.2021.105312_bib37","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1128\/IAI.00969-10","article-title":"Generation of a neutralizing human monoclonal antibody Fab fragment to surface antigen 1 of Toxoplasma gondii tachyzoites","volume":"79","author":"Fu","year":"2011","journal-title":"Infect. Immun."},{"key":"10.1016\/j.micpath.2021.105312_bib38","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/IAI.68.2.969-972.2000","article-title":"Intranasal immunization with Toxoplasma gondii SAG1 induces protective cells into both NALT and GALT compartments","volume":"68","author":"Velge-Roussel","year":"2000","journal-title":"Infect. Immun."},{"key":"10.1016\/j.micpath.2021.105312_bib39","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1016\/j.vaccine.2011.04.044","article-title":"MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8(+) T lymphocytes","volume":"29","author":"Mendes","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2021.105312_bib40","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.exppara.2006.02.005","article-title":"Toxoplasma gondii: immunogenicity and protection by P30 peptides in a murine model","volume":"114","author":"Siachoque","year":"2006","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.micpath.2021.105312_bib41","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1128\/IAI.66.9.4503-4506.1998","article-title":"Protective effect of vaccination with a combination of recombinant surface antigen 1 and interleukin-12 against toxoplasmosis in mice","volume":"66","author":"Letscher-Bru","year":"1998","journal-title":"Infect. Immun."},{"key":"10.1016\/j.micpath.2021.105312_bib42","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1016\/j.vaccine.2019.07.098","article-title":"Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood","volume":"37","author":"Laup\u00e8ze","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2021.105312_bib43","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.micpath.2021.105312_bib44","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.3389\/fimmu.2017.01833","article-title":"Co-stimulation of BCR and toll-like receptor 7 increases somatic hypermutation, memory B cell formation, and secondary antibody response to protein antigen","volume":"8","author":"Castiblanco","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2021.105312_bib45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4049\/immunohorizons.1700063","article-title":"Recent advances in the discovery and delivery of TLR7\/8 agonists as vaccine adjuvants","volume":"2","author":"Dowling","year":"2018","journal-title":"Immunohorizons"},{"key":"10.1016\/j.micpath.2021.105312_bib46","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature09737","article-title":"Programming the magnitude and persistence of antibody responses with innate immunity","volume":"470","author":"Kasturi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.micpath.2021.105312_bib47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1477-3155-12-17","article-title":"A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7","volume":"12","author":"Fox","year":"2014","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.micpath.2021.105312_bib48","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fimmu.2018.00317","article-title":"Targeted delivery of Toxoplasma gondii antigens to dendritic cells promote immunogenicity and protective efficiency against toxoplasmosis","volume":"9","author":"Lakhrif","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2021.105312_bib49","doi-asserted-by":"crossref","first-page":"6836","DOI":"10.1182\/blood-2011-07-367615","article-title":"Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity","volume":"118","author":"Tacken","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.micpath.2021.105312_bib50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jconrel.2014.07.040","article-title":"Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study","volume":"192","author":"Cruz","year":"2014","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.micpath.2021.105312_bib51","doi-asserted-by":"crossref","first-page":"102922","DOI":"10.1016\/j.ebiom.2020.102922","article-title":"New chimeric TLR7\/NOD2 agonist is a potent adjuvant to induce mucosal immune responses","volume":"58","author":"Gutjahr","year":"2020","journal-title":"EBioMedicine"}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401021005866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401021005866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:48:31Z","timestamp":1760111311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401021005866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":51,"alternative-id":["S0882401021005866"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2021.105312","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-delivery of PLGA nanoparticles loaded with rSAG1 antigen and TLR ligands: An efficient vaccine against chronic toxoplasmosis","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2021.105312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105312"}}